Expert commentaries from clinicians and researchers on clinical trials, guidelines and topical issues in diabetes care.
EASD 2020 interviews
09-29-2020 | EASD 2020 | Conference coverage | Article
EMPEROR-Reduced: Time for a change in the HF guidelines?
Miles Fisher comments on the findings from the EMPEROR-Reduced trial, which demonstrated cardioprotective effects of empagliflozin irrespective of diabetes in patients with heart failure, and discusses whether SGLT2 inhibitors should be incorporated into heart failure treatment guidelines (5:08).
09-24-2020 | EASD 2020 | Conference coverage | Article
COVID-19 and diabetes: The current evidence
Juliana Chan outlines current knowledge about the relationship between diabetes and COVID-19, discussing risk factors for poor outcomes in people with both conditions and the need for collaborative efforts to improve patient care (7:09).
ADA 2020 interviews
06-18-2020 | ADA 2020 | Conference coverage | Video
Expert commentary: The VERTIS-CV trial
Francesco Giorgino comments on the findings from the VERTIS-CV trial, and discusses the cardiovascular efficacy and safety of ertugliflozin in the context of the SGLT2 inhibitor class (10:10).
06-16-2020 | ADA 2020 | Conference coverage | Video
Researcher comment: The VERTIS-CV trial
Lead investigator Chris Cannon discusses the VERTIS-CV trial, showing that the SGLT2 inhibitor ertugliflozin is noninferior to placebo for the prevention of major adverse cardiovascular events in patients with type 2 diabetes and established atherosclerotic cardiovascular disease (7:16).
View more videos commentaries
Featuring expert interviews from our 2019 conference coverage.
Luigi Gnudi, Miles Fisher, Hiddo Heerspink, Milton Packer, Ramzi Ajjan, Juliana Chan, Francesco Giorgino, Chris Cannon, Matthew Crowley, Jay Shubrook